{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:07:48Z","timestamp":1774969668152,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Ovarian tissue cryopreservation (<jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content>) is increasingly offered to women in need of fertility preservation. However, little is known about the risk of these women dying before they use the preserved material.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>From 1999 to 2016, 927 girls and women underwent <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content> in our center, before receiving gonadotoxic treatment. All patients were without disseminated disease and with an estimated chance of survival after 5\u00a0years of &gt;50%. For each patient the specific indication for <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content> was noted, and through a national registry linked to a personal identification number, we were able to identify those who had died and the date and cause of death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By December 2017, 124\/927 patients had died from their disease (13%). The highest relative prevalence of death was seen in patients with liver cancer (2\/2; 100%), gall bladder cancer (2\/2; 100%), stomach cancer (1\/1; 100%), hemophagocytic lymphohistiocytosis (2\/3; 66%), scleroderma (1\/2; 50%), and sarcoma (24\/78; 31%). The lowest risk of dying was seen in the group of individuals with non\u2010Hodgkin lymphoma (3\/30; 10%) and breast cancer (31\/313; 10%). The shortest time from <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content> to death was seen in those with hemophagocytic lymphohistiocytosis (mean interval 0.25\u00a0years), gall bladder cancer, non\u2010Hodgkin disease and acute myeloid leukemia (mean interval 0.7\u00a0years) and the longest time from <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content> to death was in women with breast cancer (mean interval 3.4\u00a0years). Of those who died, 34 had received chemotherapy at some point before <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content>, indicating a relapse or non\u2010responsiveness to the initial treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with upper gastrointestinal cancers and sarcoma had the highest risk of dying from their disease. Breast cancer patients had the lowest risk. This knowledge may guide clinicians in their decisions on whether to offer <jats:styled-content style=\"fixed-case\">OTC<\/jats:styled-content> to girls and younger women with a life\u2010threatening disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.13576","type":"journal-article","created":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T07:18:32Z","timestamp":1550301512000},"page":"625-629","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue"],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-513X","authenticated-orcid":false,"given":"Kirsten Tryde","family":"Macklon","sequence":"first","affiliation":[{"name":"The Fertility Clinic, section 4071 University Hospital of Copenhagen Rigshospitalet Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1614676"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.47"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.1914"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/7.6.535"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4594-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70140-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.08.031"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003782017"},{"key":"e_1_2_10_11_1","unstructured":"EngholmG FerlayJ ChristensenN et\u00a0al.NORDCAN: Cancer Incidence Mortality Prevalence and Survival in the Nordic Countries Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries. Danish Cancer Society. Available fromhttp:\/\/ancr.nu"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev230"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2010.10.015"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg500"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deu158"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex040"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12934"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.13576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.13576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aogs.13576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.13576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T23:55:35Z","timestamp":1694390135000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.13576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/aogs.13576"],"URL":"https:\/\/doi.org\/10.1111\/aogs.13576","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"2018-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}